ArticleAdvances in therapy2026
A 3-Year Post-Marketing Surveillance Study of EX-PRESS™ Glaucoma Filtration Device in Japanese Eyes.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA post-marketing surveillance study of EX-PRESS™ Glaucoma Filtration Device was conducted to confirm the safety and efficacy of the product in clinical settings.
methodsPatients with glaucoma with insufficient intraocular pressure (IOP) reduction despite glaucoma medication, laser therapy or prior glaucoma surgery underwent EX-PRESS™ filtration surgery and were followed for 3 years.
resultsThe study was conducted from July 2012 to December 2017 and included 890 eyes of 835 patients from 52 medical institutions across Japan. The efficacy analysis of 821 eyes showed that the mean ± SD IOP changed from 25.0 ± 9.1 mmHg at baseline to postoperative 14.0 ± 5.4, 14.2 ± 5.8, and 14.5 ± 5.8 mmHg at 12, 24, and 36 months, respectively. The mean ± SD number of glaucoma medications used reduced from 3.5 ± 1.4 at baseline to postoperative 1.0 ± 1.5, 1.4 ± 1.7, and 1.7 ± 1.7 at 12, 24, and 36 months, respectively. The survival analysis showed that the rate of success, defined as IOP ≤ 21 mmHg and a percent reduction of ≥ 20% with or without glaucoma medication, was 64.6% at 3 years postoperatively. In the safety analysis of 824 eyes, the incidence of malfunctions was 31.9% and the incidence of adverse events (AEs) for which a causal relationship could not be ruled out was 22.2%. There were no reports of infection. The most common malfunctions were device-iris touch (26.9%), device malfunction (2.9%), device-cornea touch (2.7%), and device obstruction (1.7%). The most common AEs were IOP increased (11.9%), corneal endothelial cell loss (5.7%), glaucoma filtration surgery (5.0%), device removal (5.0%), hypotony (3.2%), and bleb reconstruction (2.4%). Five cases of reduced visual acuity and one case of visual field defect aggravation were reported as adverse events related to vision. The mean endothelial cell density (ECD) decreased after surgery but remained above 2000 cells/mm
conclusionThe current study confirmed the efficacy and safety of the EX-PRESS™ Glaucoma Filtration Device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.